104 Results for "

Del

" in MedChemExpress (MCE) Product Catalog:
Products (104)

104 Results for "Del" in MCE Product Catalog:

29
29 Publications Verification
Cat. No.: HY-13017
CAS No.: 873054-44-5
Purity:  99.97%
Synonyms: VX-770
Target:  

CFTR Autophagy

Research Areas:  

Endocrinology

Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively.
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-15448
CAS No.: 1152311-62-0
Purity:  99.85%
Synonyms: VX-661
Target:  

CFTR

Research Areas:  

Cancer

Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-112823
CAS No.: 1899921-05-1
Purity:  99.83%
Synonyms: HS-10296
Target:  

EGFR

Research Areas:  

Cancer

Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-112823A
CAS No.: 2134096-06-1
Purity:  99.67%
Synonyms: HS-10296 mesylate
Target:  

EGFR

Research Areas:  

Cancer

Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-112823B
CAS No.: 2134096-03-8
Purity:  99.77%
Synonyms: HS-10296 hydrochloride
Target:  

EGFR

Research Areas:  

Cancer

Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-18750
CAS No.: 1626387-80-1
Synonyms: AZD3759
Zorifertinib (AZD3759) is a potent, orally active, BBB-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFR wt, EGFR L858R, and EGFR exon 19Del, respectively. Zorifertinib induces cancer cell apoptosis. Zorifertinib has antitumor activity, and can be used for NSCLC, HCC etc. research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-123921
CAS No.: 2230821-27-7
Purity:  99.98%
Target:  

PROTACs EGFR

Research Areas:  

Cancer

Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a von Hippel-Lindau ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18932
CAS No.: 181223-80-3
Target:  

ERK Apoptosis

Research Areas:  

Cancer

DEL-22379 is an ERK dimerization Inhibitor. DEL-22379 readily binds to ERK2 with a Kd estimated in the low micromolar range, though binding is detectable even at low nanomolar concentrations. ERK2 dimerization is progressively inhibited with an IC50 of ~0.5 μM.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-111099
CAS No.: 1654725-02-6
Purity:  99.86%
Synonyms: ABBV-974
Target:  

CFTR Autophagy

Research Areas:  

Others

GLPG1837 is a potent and reversible CFTR potentiator, with EC50s of 3 nM and 339 nM for F508del and G551D CFTR, respectively.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19970
CAS No.: 774549-97-2
Target:  

CFTR Autophagy

Research Areas:  

Endocrinology

KM11060 is a corrector of the F508 deletion (F508del)-cystic fibrosis transmembrane conductance regulator (CFTR) trafficking defect. KM11060 can be used for the research of F508del-CFTR processing defect and development of cystic fibrosis research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13017S
CAS No.: 1413431-07-8
Purity:  99.83%
Synonyms: VX-770-d9
Ivacaftor-d9 is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-126394
CAS No.: 2204245-48-5
Purity:  99.09%
Synonyms: VX-659
Target:  

CFTR

Research Areas:  

Endocrinology

Bamocaftor (VX-659) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor can be used combine with Tezacaftor (HY-15448) and Ivacaftor (HY-13017) in cystic fibrosis research .
loading...
    loading...
Cat. No.: HY-129550
CAS No.: 2664214-60-0
Purity:  99.28%
Target:  

EGFR

Research Areas:  

Cancer

BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM). BI-4020 also shows activity against EGFR wt (IC50=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties .
loading...
    loading...
Cat. No.: HY-156698
CAS No.: 2570251-68-0
Purity:  98.64%
Target:  

PROTACs EGFR

Research Areas:  

Cancer

HJM-561 is a selective and effective orally active EGFR PROTAC degrader. HJM-561 is able to overcome the triple EGFR mutations that are resistant to Osimertinib (HY-15772). HJM-561 exhibits potent degradation of EGFR Del19/T790M/C797S (DC50: 9.2 nM) and L858R/T790M/C797S (DC50: 5.8 nM), and has anti-tumor activity (pink: EGFR ligand (HY-12857); blue: CRBN ligand (HY-A0003); black: linker) .
loading...
    loading...
Cat. No.: HY-59219
CAS No.: 411235-57-9
Cyclopropylboronic acid is an intermediate. Cyclopropylboronic acid can be used to synthesize EGFR kinase inhibitor (Compound 25). Compound 25 has antiproliferative effects on EGFR mutant (EGFR Δ19del/T790M/C797S) cells. Cyclopropylboronic acid can be used in lung cancer research .
loading...
    loading...
Cat. No.: HY-175200
Target:  

Slit Proteins

Research Areas:  

Neurological Disease Cancer

DEL-S1 is a SLIT2 binder. DEL-S1 significantly inhibits the formation of the SLIT2/ROBO1 complex by inducing conformational rearrangement, and further suppresses its function, with an IC50 of 68.8 μM. DEL-S1 can be used in studies of neurodevelopment, immunomodulation, and cancers such as glioblastoma .
loading...
    loading...
Cat. No.: HY-111772A
CAS No.: 2229860-99-3
Purity:  99.44%
Synonyms: (R)-VX-445
Target:  

Drug Isomer CFTR

Research Areas:  

Inflammation/Immunology

(R)-Elexacaftor ((R)-VX-445) is the enantiomer of Elexacaftor (HY-111772). Elexacaftor is an orally active CFTR modulator that targets nucleotide-binding domain 1. Elexacaftor stabilizes misfolded F508del-CFTR protein, enhances its trafficking to the plasma membrane, and significantly improves metabolic stability, thermal stability and ion conductivity. Elexacaftor not only restores chloride transport function in nasal epithelial cells and rescues multiple CFTR mutation subtypes, but also exerts multiplicative synergistic effects with Ivacaftor (HY-13017), and is often used in a triple combination therapy with Tezacaftor (HY-15448). Elexacaftor is widely used in basic and clinical translational research on cystic fibrosis .
loading...
    loading...
Cat. No.: HY-12972
CAS No.: 1776112-90-3
Purity:  99.34%
Synonyms: PF-06747775
Target:  

EGFR

Research Areas:  

Cancer

Mavelertinib is a selective, orally available and irreversible EGFR tyrosine kinase inhibitor (EGFR TKI), with IC50s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively. Mavelertinib can be used for the research of non-small-cell lung cancer (NSCLC) .
loading...
    loading...
Cat. No.: HY-15448A
CAS No.: 1226709-85-8
Synonyms: (Rac)-VX-661
Target:  

CFTR

Research Areas:  

Inflammation/Immunology

(Rac)-Tezacaftor ((Rac)-VX-661) is a racemate of Tezacaftor (HY-15448). Tezacaftor is a F508del CFTR corrector. (Rac)-Tezacaftor can be used for the research of cystic fibrosis .
loading...
    loading...
Cat. No.: HY-15448S
CAS No.: 1961280-24-9
Purity:  ≥97.0%
Synonyms: VX-661-d4
Tezacaftor-d4 (VX-661-d4) is the deuterium-labeled Tezacaftor (HY-15448), a F508del CFTR corrector. Tezacaftor helps CFTR protein reach the cell surface .
loading...
    loading...